Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Other neoplasm 4Breast 4Head & Neck 3Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sulindac × Dermatologic × Clear all
NCT00755976 2014-12-31

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Cancer Trials Ireland

Phase 2 Completed
32 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡